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Background-—Apolipoprotein CIII (apo CIII) is a crucial player in triglyceride-rich lipoprotein metabolism, but may also act
pleiotropically, provoking inﬂammatory responses and stimulating coagulation. Elevated apoCIII plasma levels have been
associated with increased activity of coagulation factors. Since these features of prothrombotic diathesis are linked with venous
thromboembolism (VTE), we hypothesized that apo CIII plays a role in VTE.
Methods and Results-—We recorded nonfatal VTE events in 1020 patients (age 63.311.4 years; 29.1% women) with or without
coronary artery disease (79.1% with coronary artery disease and 20.9% without coronary artery disease) during a long follow-up.
Complete plasma lipid and apolipoproteins were available for all patients. Forty-ﬁve patients (4.4%) experienced nonfatal VTE
events during a median follow-up period of 144 months. Apo CIII plasma concentration at enrollment was higher in patients with
VTE compared with patients without VTE (12.2 [95% CI, 11.10–13.5] mg/dL vs 10.6 [95% CI, 10.4–10.9] mg/dL, respectively;
P=0.011). Patients with apo CIII levels above the median value (10.6 mg/dL) exhibited an increased risk of VTE (incidence rate, 6.0
[95% CI, 4.0–8.0] vs 1.8 [95% CI, 0.7–2.9] VTE events/1000 person-years; unadjusted hazard ratio [HR], 3.42 [95% CI, 1.73–6.75];
P<0.001). This association was conﬁrmed after adjustment for sex, age, coronary artery disease diagnosis, body mass index,
hypertension, and anticoagulant treatment at enrollment (HR, 2.66; 95% CI, 1.31–5.37 [P=0.007]), with inclusion of lipid
parameters in the Cox model (HR, 3.74; 95% CI, 1.24–11.33 [P=0.019]), and even with exclusion of patients who died at follow-up
(HR, 3.92; 95% CI, 1.68–9.14 [P=0.002]) or patients taking anticoagulants (HR, 3.39; 95% CI, 1.72–6.69 [P<0.001]).
Conclusions-—Our results suggest that high plasma apo CIII concentrations may predict an increased risk of VTE in patients with
cardiovascular disease. ( J Am Heart Assoc. 2019;8:e010973. DOI: 10.1161/JAHA.118.010973.)
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A polipoprotein CIII (apo CIII) is the most important markerof triglyceride-rich lipoproteins,1 and it is a causal risk
factor for cardiovascular diseases. Increased apo CIII serum
concentrations are a primary predisposing condition for the
development of atherosclerotic disease (see reference 2 for a
review and meta-analysis). Recent data reported that rare
loss-of-function genetic variants of APOC3 gene substantially
reduce cardiovascular risk, further and strongly supporting the
direct atherogenic effects of apo CIII.3 High levels of apo CIII
have been demonstrated to be an important predictor of total
and cardiovascular mortality in the setting of secondary
prevention for coronary artery disease (CAD).4 Apo CIII
primarily inﬂuences lipid and lipoprotein metabolism, and it
also provokes inﬂammatory and atherogenic responses in
monocytes and endothelial cells.5,6 Accordingly, a great deal
of the scientiﬁc evidence is focused on the harmful role of apo
CIII in arterial vessels and in atherosclerosis-related diseases.
Several years ago, we suggested a novel potential detrimen-
tal role of apo CIII by demonstrating that elevated circulating
levels of apo CIII (but not other lipids or apolipoproteins) were
involved in a progressive increase in factor II (FII) coagulant
activity in the plasma of patients with or without CAD.7 The
extent of this increase in patients in the top quartile of apo CIII
concentration was comparable to that in carriers of the FII
G20210A allele. Therefore, from this functional point of view,
elevated apo CIII concentrations were equivalent to carrying the
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G20210A allele, a genetic condition well known as a predis-
posing factor for both arterial and venous thrombotic disease.
This evidence implies an increased propensity to form venous
thrombosis in patients exhibiting high apo CIII plasma levels.
However, after our ﬁrst report, the relationship of apo CIII
with the coagulation pathway and its association with the
incidence of venous thromboembolism (VTE) has not been
investigated further. Moreover, an objective limitation of our
previous results is that they were obtained from a retrospective
analysis and were intrinsically ﬂawed by the cross-sectional
study design.5 Therefore, as a natural corollary of the ﬁrst study,
we planned a follow-up study of the population of previously
enrolled patients for whom basal values of apo CIII were
available to investigate the clinical consequences of the
potential procoagulant effects of high plasma apo CIII concen-
trations. Speciﬁcally, we systematically collected, recorded,
and quantiﬁed nonfatal VTE events that occurred in patients
who survived for a sufﬁciently long period of follow-up to verify
whether patients with higher apo CIII concentrations exhibited
an increased risk of VTE, which would provide clinical support
for our hypothesis of apo CIII–related prothrombotic diathesis.
Methods
The data that support the ﬁndings of this study are available
from the corresponding author upon reasonable request.
Study Population
The population for this study was selected from the cohort of
the VHS (Verona Heart Study). The VHS is an ongoing survey
that uses cross-sectional and prospective designs aimed to
search for new risk factors for CAD in patients using
objective, angiographic documentation of their coronary
vessels. Details of the enrollment criteria have been carefully
described elsewhere (reference 3, appendix material 4,7). The
ethics committee of our institution (Azienda Ospedaliera
Universitaria Integrata, Verona, Italy) approved the study.
Informed written consent was obtained from all participants
after a full explanation of the study.
A total of 1020 patients (723 men and 297 women) who
lived in the District of Verona and for whom prospective data
were available were included in this study. Blood samples and
a complete clinical history were obtained in the days
preceding the execution of the coronary arteriography at
enrollment. On the basis of an angiographic evaluation, the
patients were classiﬁed as CAD-free (n=213, individuals who
underwent coronary angiography for reasons other than
suspected CAD, primarily valvular heart disease) and patients
with CAD (n=807 individuals with at least 1 of the major
epicardial coronary arteries [left anterior descending, circum-
ﬂex, and right] affected by ≥1 signiﬁcant stenosis [≥50%
lumen reduction]).
Assessment of Outcome
The patients were followed until death or June 2017. Survival
times were calculated starting from the date of enrollment (ie,
some days before the execution of the coronary angiography,
which was requested for the enrollment in our cardiovascular
cohort). The status of the study patients was determined via
search of the national population register to ascertain
mortality status. The electronic medical records of all
hospitals in the District of Verona, Northeast Italy, including
data of emergency unit admissions, were obtained for all
patients. Ambulatory or telephone survey was performed in
case of clinical doubt. To be included in the statistical
computation, nonfatal VTE events had to be conﬁrmed and
validated by 2 independent researchers after careful evalua-
tion of all the available information. As a rule, events were
adjudicated when both of the following criteria were met:
(1) clinical signs and symptoms of deep venous thrombosis or
pulmonary embolism in combination with (2) conﬁrmation on
medical imaging (eg, compression ultrasonography, venogra-
phy, spiral computed tomography, perfusion-ventilation scan,
or pulmonary angiography).
Laboratory Testing
Samples of venous blood were drawn from each patient at
enrollment after an overnight fast. Serum lipids, apolipopro-
teins, and other routine biochemical parameters were
assayed as previously described.4 Plasma apo CIII
Clinical Perspective
What Is New?
• High plasma levels of apolipoprotein CIII (apo CIII), which is
a crucial regulator of lipoproteins and a recognized risk
factor for atherosclerosis and ischemic heart disease, may
predict an increased risk of venous thromboembolic events
in a cohort of patients with cardiovascular disease.
• This result appears consistent with earlier works suggesting
that apo CIII is associated with a prothrombotic diathesis.
What Are the Clinical Implications?
• Apo CIII may provide information about the individual
procoagulant propensity and the related risk of venous
thromboembolism, potentially being a useful index for
personalized therapeutic choices in clinical practice.
• Moreover, speculatively, apo CIII–lowering drugs, including
the new anti-apo CIII antisense oligonucleotides, may
exhibit additional and unexpected antithrombotic effects.
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concentrations were measured using a fully automated
turbidimetric immunoassay.4 The reagent was obtained from
Wako Pure Chemical Industries, and the procedure recom-
mended by the manufacturer was implemented on an RXL
Dimension Analyzer (Dade International Inc.). All testing was
performed in duplicate. The intra-assay coefﬁcients of
variation were 1.84%, 2.02%, and 1.98% on 3 pools of control
sera with low, medium, and high concentrations of apo CIII,
respectively. The interassay coefﬁcients of variation were
4.4%, 3.4%, and 2.29% for low, medium, and high apo CIII
concentrations, respectively.
Statistical Analysis
All calculations were performed using SPSS 23.0 (SPSS Inc)
and R version 3.5.1 (R Foundation for Statistical Computing,
2018. https://www.R-project.org/, accessed November
2018) statistical packages. Distributions of continuous vari-
ables in groups are expressed as the meansSDs. Skewed
variables, including apo CIII, apolipoprotein E, triglyceride,
high-sensitivity C-reactive protein, and serum creatinine, were
logarithmically transformed, and geometric means with 95%
CIs are reported. Quantitative data were assessed using
Student t test. The correlation between quantitative variables
was assessed using Pearson correlation coefﬁcient (R).
Categorical data were analyzed using the chi-square test
and chi-square for linear trend analysis when indicated. VTE
event rates during the follow-up period were assessed using
the Kaplan–Meier method (log-rank statistic) and Cox regres-
sion. Kaplan–Meier curves were used for survival plots, which
stratiﬁed the study population on the basis of median apo CIII
value. Multivariate Cox proportional hazards for VTE events
were performed considering the median apo CIII value as the
threshold and including sex, age, CAD diagnosis, body mass
index, hypertension, anticoagulant treatment (the main
demographic and clinical characteristics or the factors
associated with VTE events based on univariate analysis),
and all plasma lipids and other apolipoproteins that correlated
with the plasma apo CIII concentration in the different
models. Incidence rates and incidence rate ratios with 95%
CIs were estimated organizing data into an event-time table
and estimating on this table a Poisson regression model with
person-years as an offset.8 P<0.05 was considered statisti-
cally signiﬁcant.
Results
After a median follow-up duration of 144 months (interquar-
tile range, 84–197 months), 45 of the 1020 patients (4.4%)
experienced nonfatal VTE events (deep venous thrombo-
sis=29 [64.4%], deep venous thrombosis+pulmonary embo-
lism=6 [13.3%], pulmonary embolism=10 [22.2%]). No VTE
events occurred during the ﬁrst month of follow-up, and all
VTE events were reported as ﬁrst (no recurrent) events.
Table 1 summarizes the main clinical and laboratory
characteristics of the study population, which are reported as
a whole and subdivided on the basis of VTE events during the
follow-up period. The composition of the population accord-
ing to the initial angiographic diagnosis (CAD or CAD-free)
was similar in patients with and without VTE events. Several
differences were observed between these 2 groups. Female
sex was more represented in the VTE group, and anticoag-
ulant treatment at enrollment was uniquely recorded in
patients who did not experience VTE events during the
follow-up period. Patients with VTE tended to exhibit an
increased body mass index and higher prevalence of
hypertension, but without formal statistical signiﬁcance
(0.10>P>0.05). The main traditional cardiovascular risk
factors in clinical history, traditional plasma lipids, high-
sensitivity C-reactive protein, and serum creatinine were not
differently distributed between patients with or without VTE
events. A total of 128 patients were reported to be treated
with anticoagulant therapy at discharge from the hospital-
ization during which they were enrolled in the VHS. All of
these patients were reported to take warfarin for atrial
ﬁbrillation.
Although plasma lipids were interrelated (Table 2), only
the plasma apo CIII concentration at enrollment was
signiﬁcantly elevated in VTE-positive patients compared with
VTE-negative patients (12.2 [95% CI, 11.10–13.5 mg/dL] vs
10.6 [95% CI, 10.4–10.9 mg/dL], P=0.011). Stratifying the
study population into quartiles according to the apo CIII
concentration revealed that VTE prevalence increased from
the lowest quartile to the highest quartile (P=0.001 by chi-
square for linear trend, Figure 1). Most patients who
experienced a VTE were characterized by high plasma apo
CIII concentrations and were included in the third and fourth
quartiles, indicating a threshold value at the median level
(10.6 mg/dL).
The Kaplan–Meier survival curves (Figure 2) demonstrated
that patients with a plasma apo CIII concentration above the
median level exhibited an increased risk of VTE (P<0.001, log-
rank test). High levels of apo CIII were associated with an 3-
fold increased risk of VTE in different Cox regression models.
This association was conﬁrmed after adjustments for sex, age,
CAD diagnosis, body mass index, hypertension, and antico-
agulant treatment at enrollment, even with inclusion of all
plasma lipid parameters in the regression model (Table 3).
These results were conﬁrmed in subgroup analyses of
surviving patients (n=643; hazard ratio, 3.92 [95% CI, 1.68–
9.14], P=0.002) and patients who were not taking anticoag-
ulant drugs at enrollment (n=892; hazard ratio, 3.39 [95% CI,
1.72–6.69], P<0.001). All of these results were conﬁrmed by
incidence rates and incidence rate ratio analyses, with
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patients with high apo CIII levels having a >3-fold increased
incidence rate of VTE than those with low apo CIII levels (6.0
[95% CI, 4.0–8.0] vs 1.8 [95% CI, 0.7–2.9] VTE events/
1000 person-years, P<0.001), even in adjusted models and
after the exclusion of patients taking anticoagulant drugs at
enrollment (Tables 4 and 5).
Discussion
To the best of our knowledge, this prospective cohort study is
the ﬁrst to investigate the association between plasma apo
CIII concentration and VTE incidence in humans. Our results
demonstrate that patients with cardiovascular disease with
Table 1. Clinical and Laboratory Characteristics of the Study Population, Considered as a Whole and Stratiﬁed According to VTE
Events During Follow-Up
Total Study Population (N=1020) No VTE (n=975) VTE (n=45) P Value*
Age, y 63.311.4 63.211.5 63.810.9 NS†
Women, % 29.1 28.4 44.4 0.021‡
CAD/CAD-free, % 79.1/20.9 79.0/21.0 82.2/17.8 NS‡
BMI, kg/m2 26.63.8 26.53.8 27.73.5 0.072†
Hypertension, % 75.5 75.0 86.7 0.075‡
Diabetes mellitus, % 21.3 21.1 24.4 NS‡
Smoking, % 57.4 57.7 48.9 NS‡
Serum creatinine, lmol/L 87.9 (86.3–89.6) 87.8 (86.2–89.4) 92.0 (77.6–109.1) NS†
hs-CRP, mg/L 3.34 (3.04–3.66) 3.33 (3.03–3.66) 3.46 (2.09–5.71) NS†
Total cholesterol, mmol/L 5.051.06 5.051.07 5.010.82 NS†
LDL cholesterol, mmol/L 3.290.87 3.300.87 3.140.64 NS†
HDL cholesterol, mmol/L 1.220.35 1.220.35 1.220.31 NS†
Triglyceride, mmol/L 1.53 (1.49–1.57) 1.53 (1.49–1.57) 1.56 (1.38–1.76) NS†
Apo A, g/L 1.290.28 1.280.27 1.320.28 NS†
Apo B, g/L 0.990.28 0.990.27 0.990.28 NS†
Apo CIII, mg/dL 10.7 (10.4–10.9) 10.6 (10.4–10.9) 12.2 (11.10–13.5) 0.011†
Apo E, g/L 0.037 (0.036–0.038) 0.037 (0.036–0.038) 0.036 (0.032–0.042) NS†
Anticoagulant therapy at enrollment, %§ 12.5 13.1 0.0 0.009‡
Apo A indicates apolipoprotein A; Apo B, apolipoprotein B; Apo CIII, apolipoprotein CIII; Apo E, apolipoprotein E; BMI, body mass index, CAD, coronary artery disease; HDL, high-density




§A total of 128 patients were reported to be treated with anticoagulant therapy at discharge from the hospitalization during which they were enrolled in the Verona Heart Study. All of these
patients were reported to take warfarin for atrial ﬁbrillation.
Table 2. Correlations of Lipid Parameters in the Entire Study Population Using Pearson Test
Apo E Apo CIII Apo B Apo AI Triglyceride HDL Cholesterol LDL Cholesterol
Total cholesterol 0.252* 0.359* 0.724* 0.223* 0.342* 0.271* 0.901*
LDL cholesterol 0.194* 0.135* 0.692* 0.005 0.121* 0.012
HDL cholesterol 0.085† 0.083† 0.065 0.735* 0.375*
Triglyceride 0.197* 0.587* 0.393* 0.177*
Apo AI 0.103* 0.289* 0.046
Apo B 0.255* 0.354*
Apo CIII 0.287*
Apo AI indicates apolipoprotein AI; Apo B, apolipoprotein B; Apo CIII, apolipoprotein CIII; Apo E, apolipoprotein E; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
*P<0.01.
†P<0.05.
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high apo CII concentrations, which is an important marker of
circulating triglyceride-rich lipoproteins, are 3 times as likely
to experience future VTE events within a long-term period (eg,
the median follow-up duration in our study was 12 years).
Forty-ﬁve VTE events were recorded in 1000 patients
affected by coronary or valvular heart disease, which is a VTE
incidence rate of 3.7 events/1000 person-years. This rate was
higher than that in the unselected general population (1.0–1.8
events/1000 person-years).9–11 Thus, as an initial observation,
the present data suggest that the VTE incidence rate in patients
with cardiovascular disease is clearly higher (by 2-fold) than
that in healthy patients. Similar results (incidence rate of 3.0
events/1000 person-years) and conclusions were reported
recently in a large population of patients (47 611 patients
followed for 3 years) with atherosclerotic vascular disease,12
which supports the hypothesis that arterial disease (rather than
CAD speciﬁcally) confers an increased risk of VTE.
Prandoni et al13 ﬁrst demonstrated the association
between VTE and subsequent arterial cardiovascular diseases,
which raised great interest14–16 but remained controversial.17,18
Consequently, the reverse association was also investigated,
and the hypothesis that traditional cardiovascular risk factors of
atherosclerosis (eg, smoking, high blood pressure, diabetes
mellitus, obesity, and dyslipidemia) are involved in the occur-
rence of VTE was substantially conﬁrmed.19,20 A recent report
on a prospective cohort of patients with VTE suggested that the
cumulative burden of conventional risk factors, rather than a
single element, is relevant to the risk of VTE occurrence.21
From this evidence, it is warranted to note the peculiar
features of our study: both groups of patients with cardio-
vascular disease with or without VTE were fully balanced for
all major traditional risk factors for arterial disease at the time
of enrollment (Table 1). Therefore, the ﬁnding that the initially
elevated apo CIII concentrations were asymmetrically dis-
tributed between the groups of patients who chronically
experienced (or not) VTE events was unexpected and
suggestive of a possible causal link. The incidence rates of
VTE for the 2 groups of patients stratiﬁed according to the
median apo CIII level (10.6 mg/dL) were 1.8 and 6.0 events/
1000 person-years, respectively. Given that the estimated
incidence of VTE in the general population is 1.0 to 1.8
events/1000 person-years,9,10 the group with low apo CIII
levels exhibited a substantially similar incidence rate as
compared with the general population (Table 4), while the
group with high apo CIII levels exhibited an 3-fold increase
in incidence rate (Table 4), which suggests a role for apo CIII
in VTE risk. No other laboratory characteristics, including any
other plasma lipid parameters, or traditional cardiovascular
risk factors were distributed so differently between the groups
with or without VTE. Women were more represented in the
VTE group (Table 1). Treatment with oral anticoagulants at
enrollment (128 patients were taking warfarin for atrial
ﬁbrillation) into our study is an important potential bias
regarding the results of the current study. Notably, such
Figure 1. Venous thromboembolism (VTE) rate during the
follow-up period among patients stratiﬁed into quartiles according
to apolipoprotein CIII (apo CIII) levels.
Figure 2. Kaplan–Meier survival curves for venous thromboem-
bolism (VTE) among patients stratiﬁed by the median level of
apolipoprotein CIII (apo CIII).
Table 3. Plasma Concentrations of Apo CIII Above the





Error Hazard Ratio P Value
Unadjusted 1.229 0.347 3.42 (1.73–6.75) <0.001
Model 1 1.154 0.349 3.17 (1.60–6.29) 0.001
Model 2 1.119 0.350 3.06 (1.54–6.08) 0.001
Model 3 0.977 0.359 2.66 (1.31–5.37) 0.007
Model 4 1.320 0.565 3.74 (1.24–11.33) 0.019
Model 1: adjusted for sex and age; model 2: adjusted for sex, age, and coronary artery
disease (CAD) diagnosis; model 3: adjusted for sex, age, CAD diagnosis, body mass index
(BMI), hypertension, and anticoagulant therapy at enrollment; model 4: adjusted for sex,
age, CAD diagnosis, BMI, hypertension, anticoagulant therapy at enrollment, and all
plasma lipid parameters (ie, total and high- and low-density lipoprotein cholesterol,
triglyceride, and apolipoproteins AI, B, and E). Apo CIII indicates apolipoprotein CIII; VTE,
venous thromboembolism.
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treatment was recorded only in a proportion of patients
without VTE but not in patients with VTE events during the
follow-up period (Table 1). The results did not change when
the risk estimate was reassessed in the warfarin-free group,
which excludes any interference of this therapy in our results.
Different regression models conﬁrmed the association of VTE
incidence with apo CIII after adjustment for all possible
confounding factors (Table 3).
These ﬁndings reﬂect a perspective survey over time, but
do not provide a direct demonstration of a causal or
mechanistic role for apo CIII in VTE. However, the results
are an ideal continuation and clinical accomplishment of
previous work from our group, in which several coagulation
activities were evaluated in the relationship with apo CIII
concentrations.4,7 Notably, the earlier results of studies on
coagulation biomarkers4,7 closely match the current study.
We ﬁrst demonstrated that thrombin generation, which
was assessed using endogenous thrombin potential, was
ampliﬁed in patients with elevated apo CIII concentrations.4
Thrombin generation occurs in the terminal portion of the
coagulation cascade, which depends on numerous
coagulation factors. For this reason, we subsequently exam-
ined the relationship of apo CIII with the plasma coagulant
activities of FII, factor V, factor VIII, activated factor VII, and
activated factor X.7 The strongest association was observed
for factor II coagulant activity, which exhibited an increase
comparable to that in carriers of the G20210A allele, a well-
known genetic predisposing factor for both arterial and
venous thrombotic disease. In the analysis, although less
strong, statistical associations of apo CIII with factor V–
mediated coagulant activity, activated factor VII levels, and
activated factor X generation were also observed.7 Experi-
ments with the speciﬁc thrombin inhibitor hirudin were
performed to separate the effects on thrombin generation
from the upstream formation of activated factor X as a result
of factor VII/tissue factor activation. This relationship was
experimentally excluded, and our interpretation was that apo
CIII acts as a modulator of prothrombinase activity by favoring
the triggering and ampliﬁcation of factor II coagulant activity
in the terminal portion of the coagulation cascade.
Taken together, these data suggest that the apo CIII–
related effect on prothrombinase activity occurs in both CAD
Table 4. IRs and IRRs With 95% CIs for VTE According to Plasma Concentrations of Apo CIII, Estimated by Different Poisson
Regression Models in the Entire Study Population (N=1020)
IR IRR
P Value
VTE Events/1000 Person-Y, No.
High Apo CIII vs Low Apo CIIILow Apo CIII <10.6 mg/dL High Apo CIII ≥10.6 mg/dL
Unadjusted 1.8 (0.7–2.9) 6.0 (4.0–8.0) 3.36 (1.76–6.94) <0.001
Model 1 1.9 (0.8–3.0) 5.6 (3.6–7.6) 3.03 (1.58–6.3) 0.002
Model 2 1.9 (0.8–3.0) 5.5 (3.5–7.5) 2.97 (1.55–6.18) 0.002
Model 3 1.8 (0.6–2.9) 4.3 (2.3–6.2) 2.42 (1.23–5.09) 0.014
Model 4 1.3 (0.1–2.4) 4.9 (2.1–7.6) 3.88 (1.41–11.99) 0.012
Model 1: adjusted for sex and age; model 2: adjusted for sex, age, and coronary artery disease (CAD) diagnosis; model 3: adjusted for sex, age, CAD diagnosis, body mass index (BMI), and
hypertension; model 4: adjusted for sex, age, CAD diagnosis, BMI, hypertension, and all plasma lipid parameters (ie, total and high- and low-density lipoprotein cholesterol, triglyceride, and
apolipoproteins AI, B, and E). Apo CIII indicates apolipoprotein CIII; IR, incidence rate; IRR, incidence rate ratio; VTE, venous thromboembolism.
Table 5. IRs and IRRs With 95% CIs for VTE According to Plasma Concentrations of Apo CIII, Estimated by Different Poisson
Regression Models in Patients Not Taking Anticoagulant Therapy at Enrollment (n=892)
IR IRR
P Value
VTE Events/1000 Person-Y, No.
High Apo CIII vs Low Apo CIIILow Apo CIII <10.6 mg/dL High Apo CIII ≥10.6 mg/dL
Unadjusted 2.1 (0.9–3.3) 6.9 (4.6–9.2) 3.33 (1.74–6.88) 0.001
Model 1 2.1 (0.8–3.3) 6.6 (4.3–8.9) 3.16 (1.65–6.56) 0.001
Model 2 2.1 (0.9–3.4) 6.5 (4.2–8.8) 3.09 (1.61–6.42) 0.001
Model 3 2.2 (0.9–3.6) 5.6 (3.3–8.0) 2.52 (1.29–5.31) 0.010
Model 4 1.2 (0.2–2.4) 4.7 (1.8–7.7) 3.99 (1.39–12.92) 0.014
Model 1: adjusted for sex and age; model 2: adjusted for sex, age, and coronary artery disease (CAD) diagnosis; model 3: adjusted for sex, age, CAD diagnosis, body mass index (BMI), and
hypertension; model 4: adjusted for sex, age, CAD diagnosis, BMI, hypertension, and all plasma lipid parameters (ie, total and high- and low-density lipoprotein cholesterol, triglyceride, and
apolipoproteins AI, B, and E). Apo CIII indicates apolipoprotein CIII; IR, incidence rate; IRR, incidence rate ratio; VTE, venous thromboembolism.
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and CAD-free patients independently of “atherosclerosis.”
Apo CIII may exert procoagulant activity on the arterial side
and the venous compartment. Moreover, taking into account
the pivotal role of thrombin in several biological pathways
beyond blood coagulation, including its major role as a
pathophysiological mediator bridging inﬂammation and
clotting,22 the detrimental and pleiotropic consequences of
elevated apo CIII concentrations to both arterial and venous
vessels appear evident. A recent prospective nested case-
control study of apparently healthy patients revealed an
association of apo CIII with CAD and high-sensitivity
C-reactive protein, a well-recognized inﬂammatory marker.23
If the hypothesis of an apo CIII–related prothrombotic
diathesis is true, then as a practical consequence, pharma-
cological treatments that lower apo CIII concentrations may
exhibit beneﬁcial effects beyond lipid metabolism, ie, sup-
pressing thrombin generation and decreasing factor II coag-
ulant activity. Several cardiovascular protective compounds
(peroxisome proliferator-activated receptor agonists, omega-3
polyunsaturated fatty acid, niacin, ezetimibe, and statins) are
effective apo CIII–lowering drugs.24 Volanesorsen, a new anti-
apo CIII antisense oligonucleotide, was demonstrated in
phase II clinical trials to be a powerful new therapy for
triglyceride-rich lipoprotein-associated dyslipidemia.25 While
there is no similar evidence for the other above-mentioned
drugs, statins (especially rosuvastatin, which is particularly
efﬁcient in reducing apo CIII levels) have been consistently
demonstrated to reduce VTE events.26 A systematic review
and meta-analysis of observational cohort studies and
randomized controlled trials (13 cohort studies comprising
3 148 259 participants and 23 randomized controlled trials of
statins vs placebo or no treatment comprising 118 464
participants) recently conﬁrmed this beneﬁcial effect.27
The coagulation cascade requires lipids, and it is greatly
accelerated by lipid binding. However, the mechanism by
which statin treatment reduces VTE risk is not clear. Our
previous and current results offer a new contribution explain-
ing this mechanism, namely, a role of apo CIII. A “threshold
effect” for the procoagulant activity of apo CIII concentrations
is consistent with the data in the present work, in which a net
increase in VTE risk was observed only for individuals with apo
CIII concentrations >10.6 mg/dL. Statins appear to lower apo
CIII concentrations to different degrees, depending on the
dosage and type of statin.28
Study Limitations
A possible limitation of the study is that symptomatic events
were retrospectively ascertained using a formal adjudication
process of 2 blinded specialists. The retrospective nature of
event collection may lead to an underascertainment of events.
Therefore, the observed event rate may underestimate the
“true” event rate. However, it is reassuring that the frequency
of patients with VHS is comparable to the literature for
analogous populations.12 Notably, the relatively few events
collected may intrinsically limit the statistical power of the
study, but the number of VTE events is consistent with the
expected frequency in real life for a population of 1000
patients with cardiovascular disease followed for 12 years.
Our data suggest 2 further considerations as working
hypotheses. The ﬁrst hypothesis is related to the potential use
of total apo CIII as a useful index for personalized therapeutic
choices in clinical practice. Apo CIII may be a more precise
predictor of cardiovascular disease risk than triglyceride con-
centrations and may provide information about the prothrom-
botic and procoagulant propensity of a single patient. Several
methods for routinely measuring total apo CIII are available, and
these methods exhibit excellent precision and may be
automated.29 Apo CIII in very low-density lipoprotein and low-
density lipoprotein subfractions may be preferable in research
settings, but this methodology may be cumbersome in practice
because it requires ultracentrifugation. The present ﬁndings
suggest that a total apo CIII assay is sufﬁcient for clinical
purposes. Second, all of the drugs that lower apo CIII concen-
trations, including the new anti-apo CIII antisense oligonu-
cleotides, may exhibit additional and unexpected antithrombotic
effects. Formal evidence of efﬁcacy in reducing VTE risk are
lacking for many of these agents, with statins as the only notable
exceptions. Therefore, future investigations and speciﬁcally
designed clinical trials are needed. In this context of uncertainty,
veriﬁcation of drug interactions and quantiﬁcation of the
hemorrhagic risk in cases of associated anticoagulant treatment
are required.
Conclusions
The data in the present work provide, for the ﬁrst time, clinical
proof of the prothrombotic role of elevated plasma apo CIII
concentrations in the setting of VTE. This conclusion is
consistent with our previous observations that high apo CIII
concentrations enhance the coagulation cascade via
increased factor II coagulant activity and ampliﬁed thrombin
generation, which are known to play crucial roles in VTE.
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